• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sepsis-induced coagulopathy: a matter of timeline.

作者信息

Meziani Ferhat, Iba Toshiaki, Levy Jerrold H, Helms Julie

机构信息

Faculté de Médecine, Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, Université de Strasbourg (UNISTRA), 1, place de l'Hôpital, 67091, Strasbourg Cedex, France.

INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France.

出版信息

Intensive Care Med. 2024 Aug;50(8):1404-1405. doi: 10.1007/s00134-024-07507-3. Epub 2024 Jun 10.

DOI:10.1007/s00134-024-07507-3
PMID:38856751
Abstract
摘要

相似文献

1
Sepsis-induced coagulopathy: a matter of timeline.脓毒症诱导的凝血病：时间线的问题
Intensive Care Med. 2024 Aug;50(8):1404-1405. doi: 10.1007/s00134-024-07507-3. Epub 2024 Jun 10.
2
Coagulopathy of sepsis from nonspecific inhibitors.非特异性抑制剂所致脓毒症凝血功能障碍
Int J Lab Hematol. 2015 Dec;37(6):e170-1. doi: 10.1111/ijlh.12415. Epub 2015 Aug 25.
3
Bacteremic consumptive coagulopathy.菌血症性消耗性凝血病
J Maine Med Assoc. 1970 Oct;61:232-5.
4
Fatal intravascular consumption coagulopathy in meningococcal sepsis.脑膜炎球菌败血症中的致死性血管内消耗性凝血病
Am J Med. 1969 Jun;46(6):910-8. doi: 10.1016/0002-9343(69)90093-x.
5
Coagulopathy in sepsis - a new look at an old problem.脓毒症中的凝血病——对一个老问题的新审视。
Anaesthesiol Intensive Ther. 2016;48(5):352-359. doi: 10.5603/AIT.a2016.0051. Epub 2016 Nov 8.
6
Plasma Hsa-miR-92a-3p in correlation with lipocalin-2 is associated with sepsis-induced coagulopathy.血浆 Hsa-miR-92a-3p 与脂联素-2 相关，与脓毒症诱导的凝血功能障碍有关。
BMC Infect Dis. 2020 Feb 19;20(1):155. doi: 10.1186/s12879-020-4853-y.
7
Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation.脓毒症诱导的凝血病和弥散性血管内凝血
Anesthesiology. 2020 May;132(5):1238-1245. doi: 10.1097/ALN.0000000000003122.
8
Coagulopathy of sepsis.脓毒症凝血功能障碍
Thromb Haemost. 2004 Feb;91(2):213-24. doi: 10.1160/TH03-03-0182.
9
Mechanisms and management of the coagulopathy of trauma and sepsis: trauma-induced coagulopathy, sepsis-induced coagulopathy, and disseminated intravascular coagulation.创伤和脓毒症凝血障碍的机制和处理：创伤诱导的凝血障碍、脓毒症诱导的凝血障碍和弥散性血管内凝血。
J Thromb Haemost. 2023 Dec;21(12):3360-3370. doi: 10.1016/j.jtha.2023.05.028. Epub 2023 Sep 16.
10
Sepsis-Induced Coagulopathy: A Prelude to DIC.脓毒症诱导的凝血病：弥散性血管内凝血的前奏。
Anesth Analg. 2024 Apr 1;138(4):695. doi: 10.1213/ANE.0000000000006943. Epub 2024 Mar 15.

引用本文的文献

1
Aspirin is associated with a reduction in mortality rate for patients with sepsis-induced coagulopathy: a retrospective cohort study.阿司匹林与脓毒症诱导的凝血病患者死亡率降低相关：一项回顾性队列研究。
Front Pharmacol. 2025 Jul 28;16:1537994. doi: 10.3389/fphar.2025.1537994. eCollection 2025.
2
GSDMD-NETs in patients with sepsis-induced coagulopathy and their interaction with glycocalyx damage.脓毒症诱导的凝血病患者中的Gasdermin D孔形成结构域与糖萼损伤的相互作用
Front Immunol. 2025 Jul 22;16:1624128. doi: 10.3389/fimmu.2025.1624128. eCollection 2025.
3
Immunothrombosis in Sepsis: Cellular Crosstalk, Molecular Triggers, and Therapeutic Opportunities-A Review.

本文引用的文献

1
Severe Pneumocystis jirovecii pneumonia: time to reassess our practices.重度耶氏肺孢子菌肺炎：是时候重新评估我们的治疗方法了。
Intensive Care Med. 2024 Aug;50(8):1310-1312. doi: 10.1007/s00134-024-07547-9. Epub 2024 Jul 29.
2
Refining trial design in sepsis management: balancing realism with ideal outcomes.优化脓毒症管理中的试验设计：平衡现实性与理想结果。
Intensive Care Med. 2024 Jul;50(7):1126-1128. doi: 10.1007/s00134-024-07521-5. Epub 2024 Jun 26.
3
How to manage coagulopathies in critically ill patients.如何管理危重症患者的凝血病。
脓毒症中的免疫血栓形成：细胞间相互作用、分子触发因素及治疗机会——综述
Int J Mol Sci. 2025 Jun 25;26(13):6114. doi: 10.3390/ijms26136114.
4
Unraveling the role of histone acetylation in sepsis biomarker discovery.揭示组蛋白乙酰化在脓毒症生物标志物发现中的作用。
Front Mol Biosci. 2025 Apr 30;12:1582181. doi: 10.3389/fmolb.2025.1582181. eCollection 2025.
5
Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy.弥散性血管内凝血：病因、分子机制、诊断与治疗
MedComm (2020). 2025 Jan 14;6(2):e70058. doi: 10.1002/mco2.70058. eCollection 2025 Feb.
6
Biomarkers of sepsis-induced coagulopathy: diagnostic insights and potential therapeutic implications.脓毒症诱导的凝血病的生物标志物：诊断见解及潜在治疗意义
Ann Intensive Care. 2025 Jan 17;15(1):12. doi: 10.1186/s13613-025-01434-2.
7
Heparin in sepsis: current clinical findings and possible mechanisms.脓毒症中的肝素：当前临床研究结果及可能机制
Front Immunol. 2024 Dec 6;15:1495260. doi: 10.3389/fimmu.2024.1495260. eCollection 2024.
Intensive Care Med. 2023 Mar;49(3):273-290. doi: 10.1007/s00134-023-06980-6. Epub 2023 Feb 17.
4
Immunohaemostasis: a new view on haemostasis during sepsis.免疫止血：脓毒症期间止血的新观点
Ann Intensive Care. 2017 Dec 2;7(1):117. doi: 10.1186/s13613-017-0339-5.
5
Thrombocytosis is a marker of poor outcome in community-acquired pneumonia.血小板增多症是社区获得性肺炎不良预后的标志物。
Chest. 2013 Mar;143(3):767-775. doi: 10.1378/chest.12-1235.